Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Ltd ( (AU:MEM) ) just unveiled an announcement.
Memphasys Limited has dispatched its prospectus for a 1-for-6 pro-rata Non-Renounceable Entitlement Issue, aiming to raise approximately $1.12 million. The funds will support the commercialisation of the Felix™ System, including regulatory approvals for the European market, and provide working capital for corporate purposes. This initiative is expected to enhance Memphasys’s market position in the fertility treatment industry by advancing the adoption and production of its Felix™ System.
More about Memphasys Ltd
Memphasys Limited is a company focused on the commercialisation of its patented Felix™ System, a novel bioseparation technology for assisted reproduction. The Felix™ System uses electrophoresis and proprietary size-exclusion membranes to isolate viable sperm cells for human fertility treatments. The company’s strategy involves securing sales contracts, fostering clinical and distribution partnerships, and scaling production capacity to establish Felix™ as a global standard in sperm selection.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
For detailed information about MEM stock, go to TipRanks’ Stock Analysis page.